LIVIVO - Search results -

Search results

Result 1 - 10 of total 10

Search options

Book: Herb, nutrient, and drug interactions

Stargrove, Mitchell B. / Treasure, Jonathan / Mckee, Dwight L.

clinical implications and therapeutic strategies

2008

Author's details	Mitchell Bebel Stargrove ; Jonathan Treasure ; Dwight L. McKee
Language	English
Size	XXVIII, 932 S.
Publisher	Mosby Elsevier
Publishing place	St. Louis, Mo
Publishing country	United States
Document type	Book
Note	Systemvoraussetzungen: Windows: Windows 2000, XP, or Vista, 800x600 pixels screen resolution, 256 colors, 128 MB RAM, runs with Internetexplorer 6.0, Netscape 7 or later, and Firefox 1.x. - Macintosh: Mac OS 10.2 or later operating system, 800x600 pixels screen resolution, 256 colors, 128 MB RAM, runs with Internet Explorer 5.2+, Netscape 7, Safari 1.x, later and Firefox 1.x
Accompanying material	1 CD-ROM (12 cm)
HBZ-ID	HT015385474
ISBN	0-323-02964-7 ; 978-0-323-02964-3
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
2007 MO 986 <<[Begleitmaterial]>>	order for loan	Magazin
2008 A 2061	order for loan	Magazin

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The "Big Five" Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein.

Naujokat, Cord / McKee, Dwight L

Current medicinal chemistry

2020 Volume 28, Issue 22, Page(s) 4321–4342

Abstract: Cancer stem cells (CSCs) constitute a subpopulation of tumor cells that possess self-renewal and tumor initiation capacity, and the ability to give rise to the heterogeneous lineages of cancer cells that comprise the tumor. CSCs exhibit intrinsic ... ...

Abstract	Cancer stem cells (CSCs) constitute a subpopulation of tumor cells that possess self-renewal and tumor initiation capacity, and the ability to give rise to the heterogeneous lineages of cancer cells that comprise the tumor. CSCs exhibit intrinsic mechanisms of resistance to virtually all conventional cancer therapeutics, allowing them to survive current cancer therapies and to initiate tumor recurrence and metastasis. Different pathways and mechanisms that confer resistance and survival of CSCs, including activation of the Wnt/β- catenin, Sonic Hedgehog, Notch, PI3K/Akt/mTOR and STAT3 signaling pathways, expression of aldehyde dehydrogenase 1 (ALDH1) and oncogenic microRNAs, and acquisition of epithelial-mesenchymal transition (EMT), have been identified recently. Certain phytochemicals, in particular curcumin, epigallocatechin-3-gallate (EGCG), sulforaphane, resveratrol and genistein have been shown to interfere with these intrinsic CSC pathways in vitro and in human xenograft mice, leading to elimination of CSCs. Moreover, recent clinical trials have demonstrated the therapeutic efficacy of five phytochemicals, alone or in combination with modern cancer therapeutics, and in various types of cancer. Since current cancer therapies fail to eradicate CSCs, leading to cancer recurrence and progression, targeting of CSCs with phytochemicals such as curcumin, EGCG, sulforaphane, resveratrol and genistein, combined with each other and/or in combination with conventional cytotoxic drugs and novel cancer therapeutics, may offer a novel therapeutic strategy against cancer.
MeSH term(s)	Animals ; Catechin/analogs & derivatives ; Curcumin/pharmacology ; Curcumin/therapeutic use ; Genistein/pharmacology ; Genistein/therapeutic use ; Hedgehog Proteins ; Humans ; Isothiocyanates ; Mice ; Neoplasm Recurrence, Local ; Neoplastic Stem Cells ; Phosphatidylinositol 3-Kinases ; Phytochemicals/pharmacology ; Resveratrol/pharmacology ; Sulfoxides
Chemical Substances	Hedgehog Proteins ; Isothiocyanates ; Phytochemicals ; Sulfoxides ; Catechin (8R1V1STN48) ; epigallocatechin gallate (BQM438CTEL) ; Genistein (DH2M523P0H) ; sulforaphane (GA49J4310U) ; Curcumin (IT942ZTH98) ; Resveratrol (Q369O8926L)
Language	English
Publishing date	2020-02-28
Publishing country	United Arab Emirates
Document type	Journal Article ; Review
ZDB-ID	1319315-6
ISSN	1875-533X ; 0929-8673
ISSN (online)	1875-533X
ISSN	0929-8673
DOI	10.2174/0929867327666200228110738
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4432: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.

Sternberg, Ariane / McKee, Dwight L / Naujokat, Cord

Current topics in medicinal chemistry

2020 Volume 20, Issue 16, Page(s) 1423–1433

Abstract: Like other human pathogenic viruses, coronavirus SARS-CoV-2 employs sophisticated macromolecular machines for viral host cell entry, genome replication and protein processing. Such machinery encompasses SARS-CoV-2 envelope spike (S) glycoprotein required ...

Abstract	Like other human pathogenic viruses, coronavirus SARS-CoV-2 employs sophisticated macromolecular machines for viral host cell entry, genome replication and protein processing. Such machinery encompasses SARS-CoV-2 envelope spike (S) glycoprotein required for host cell entry by binding to the ACE2 receptor, viral RNA-dependent RNA polymerase (RdRp) and 3-chymotrypsin-like main protease (3Clpro/Mpro). Under the pressure of the accelerating COVID-19 pandemic caused by the outbreak of SARS-CoV-2 in Wuhan, China in December 2019, novel and repurposed drugs were recently designed and identified for targeting the SARS-CoV-2 reproduction machinery, with the aim to limit the spread of SARS-CoV-2 and morbidity and mortality due to the COVID-19 pandemic.
MeSH term(s)	Antiviral Agents/therapeutic use ; Betacoronavirus/drug effects ; Coronavirus Infections/drug therapy ; Coronavirus Infections/virology ; Cysteine Endopeptidases ; Drug Repositioning ; Humans ; Pandemics ; Peptidyl-Dipeptidase A/chemistry ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/virology ; RNA Replicase/antagonists & inhibitors ; Spike Glycoprotein, Coronavirus/antagonists & inhibitors ; Viral Nonstructural Proteins/antagonists & inhibitors ; Virus Internalization ; Virus Replication
Chemical Substances	Antiviral Agents ; Spike Glycoprotein, Coronavirus ; Viral Nonstructural Proteins ; spike protein, SARS-CoV-2 ; RNA Replicase (EC 2.7.7.48) ; RNA-dependent RNA polymerase, coronavirus (EC 2.7.7.48) ; Peptidyl-Dipeptidase A (EC 3.4.15.1) ; angiotensin converting enzyme 2 (EC 3.4.17.-) ; 3C-like proteinase, Coronavirus (EC 3.4.22.-) ; Cysteine Endopeptidases (EC 3.4.22.-)
Keywords	covid19
Language	English
Publishing date	2020-05-19
Publishing country	United Arab Emirates
Document type	Journal Article
ZDB-ID	2064823-6
ISSN	1873-4294 ; 1568-0266
ISSN (online)	1873-4294
ISSN	1568-0266
DOI	10.2174/1568026620999200517043137
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5572: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery

Sternberg, Ariane / McKee, Dwight L / Naujokat, Cord

Curr Top Med Chem

Abstract	Like other human pathogenic viruses, coronavirus SARS-CoV-2 employs sophisticated macromolecular machines for viral host cell entry, genome replication and protein processing. Such machinery encompasses SARS-CoV-2 envelope spike (S) glycoprotein required for host cell entry by binding to the ACE2 receptor, viral RNA-dependent RNA polymerase (RdRp) and 3-chymotrypsin-like main protease (3Clpro/Mpro). Under the pressure of the accelerating COVID-19 pandemic caused by the outbreak of SARS-CoV-2 in Wuhan, China in December 2019, novel and repurposed drugs were recently designed and identified for targeting the SARS-CoV-2 reproduction machinery, with the aim to limit the spread of SARS-CoV-2 and morbidity and mortality due to the COVID-19 pandemic.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #285738
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery

Sternberg, Ariane / McKee, Dwight L. / Naujokat, Cord

Current Topics in Medicinal Chemistry

2020 Volume 20, Issue 16, Page(s) 1423–1433

Abstract	Like other human pathogenic viruses, coronavirus SARS-CoV-2 employs sophisticated macromolecular machines for viral host cell entry, genome replication and protein processing. Such machinery encompasses SARS-CoV-2 envelope spike (S) glycoprotein required for host cell entry by binding to the ACE2 receptor, viral RNA-dependent RNA polymerase (RdRp) and 3-chymotrypsin-like main protease (3Clpro/Mpro). Under the pressure of the accelerating COVID-19 pandemic caused by the outbreak of SARS-CoV-2 in Wuhan, China in December 2019, novel and repurposed drugs were recently designed and identified for targeting the SARS-CoV-2 reproduction machinery, with the aim to limit the spread of SARS-CoV-2 and morbidity and mortality due to the COVID-19 pandemic.
Keywords	Drug Discovery ; General Medicine ; covid19
Language	English
Publisher	Bentham Science Publishers Ltd.
Publishing country	nl
Document type	Article ; Online
ZDB-ID	2064823-6
ISSN	1873-4294 ; 1568-0266
ISSN (online)	1873-4294
ISSN	1568-0266
DOI	10.2174/1568026620999200517043137
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

In stock of ZB MED Cologne/Königswinter

Zs.A 5572: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Candidate drugs against SARS-CoV-2 and COVID-19.

McKee, Dwight L / Sternberg, Ariane / Stange, Ulrike / Laufer, Stefan / Naujokat, Cord

Pharmacological research

2020 Volume 157, Page(s) 104859

Abstract: Outbreak and pandemic of coronavirus SARS-CoV-2 in 2019/2020 will challenge global health for the future. Because a vaccine against the virus will not be available in the near future, we herein try to offer a pharmacological strategy to combat the virus. ...

Abstract	Outbreak and pandemic of coronavirus SARS-CoV-2 in 2019/2020 will challenge global health for the future. Because a vaccine against the virus will not be available in the near future, we herein try to offer a pharmacological strategy to combat the virus. There exists a number of candidate drugs that may inhibit infection with and replication of SARS-CoV-2. Such drugs comprise inhibitors of TMPRSS2 serine protease and inhibitors of angiotensin-converting enzyme 2 (ACE2). Blockade of ACE2, the host cell receptor for the S protein of SARS-CoV-2 and inhibition of TMPRSS2, which is required for S protein priming may prevent cell entry of SARS-CoV-2. Further, chloroquine and hydroxychloroquine, and off-label antiviral drugs, such as the nucleotide analogue remdesivir, HIV protease inhibitors lopinavir and ritonavir, broad-spectrum antiviral drugs arbidol and favipiravir as well as antiviral phytochemicals available to date may limit spread of SARS-CoV-2 and morbidity and mortality of COVID-19 pandemic.
MeSH term(s)	Angiotensin-Converting Enzyme 2 ; Angiotensin-Converting Enzyme Inhibitors/pharmacology ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Betacoronavirus/drug effects ; COVID-19 ; Coronavirus Infections/drug therapy ; Coronavirus Infections/epidemiology ; Coronavirus Infections/mortality ; Humans ; Pandemics ; Peptidyl-Dipeptidase A/drug effects ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/mortality ; SARS-CoV-2 ; Serine Endopeptidases/drug effects ; Serine Proteinase Inhibitors/pharmacology
Chemical Substances	Angiotensin-Converting Enzyme Inhibitors ; Antiviral Agents ; Serine Proteinase Inhibitors ; Peptidyl-Dipeptidase A (EC 3.4.15.1) ; ACE2 protein, human (EC 3.4.17.23) ; Angiotensin-Converting Enzyme 2 (EC 3.4.17.23) ; Serine Endopeptidases (EC 3.4.21.-) ; TMPRSS2 protein, human (EC 3.4.21.-)
Keywords	covid19
Language	English
Publishing date	2020-04-29
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	1003347-6
ISSN	1096-1186 ; 0031-6989 ; 1043-6618
ISSN (online)	1096-1186
ISSN	0031-6989 ; 1043-6618
DOI	10.1016/j.phrs.2020.104859
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 721: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Candidate drugs against SARS-CoV-2 and COVID-19

McKee, Dwight L. / Sternberg, Ariane / Stange, Ulrike / Laufer, Stefan / Naujokat, Cord

Pharmacological Research

2020 Volume 157, Page(s) 104859

Keywords	Pharmacology ; covid19
Language	English
Publisher	Elsevier BV
Publishing country	us
Document type	Article ; Online
ISSN	1043-6618
DOI	10.1016/j.phrs.2020.104859
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article: Candidate drugs against SARS-CoV-2 and COVID-19

McKee, Dwight L / Sternberg, Ariane / Stange, Ulrike / Laufer, Stefan / Naujokat, Cord

Pharmacol Res

Abstract	Outbreak and pandemic of coronavirus SARS-CoV-2 in 2019/2020 will challenge global health for the future. Because a vaccine against the virus will not be available in the near future, we herein try to offer a pharmacological strategy to combat the virus. There exists a number of candidate drugs that may inhibit infection with and replication of SARS-CoV-2. Such drugs comprise inhibitors of TMPRSS2 serine protease and inhibitors of angiotensin-converting enzyme 2 (ACE2). Blockade of ACE2, the host cell receptor for the S protein of SARS-CoV-2 and inhibition of TMPRSS2, which is required for S protein priming may prevent cell entry of SARS-CoV-2. Further, chloroquine and hydroxychloroquine, and off-label antiviral drugs, such as the nucleotide analogue remdesivir, HIV protease inhibitors lopinavir and ritonavir, broad-spectrum antiviral drugs arbidol and favipiravir as well as antiviral phytochemicals available to date may limit spread of SARS-CoV-2 and morbidity and mortality of COVID-19 pandemic.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #32360480
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Book: Herb, nutrient, and drug interactions

Stargrove, Mitchell Bebel / Treasure, Jonathan / McKee, Dwight L

clinical implications and therapeutic strategies

2008

Author's details	Mitchell Bebel Stargrove, Jonathan Treasure, Dwight L. McKee
MeSH term(s)	Herb-Drug Interactions ; Food-Drug Interactions
Language	English
Size	xxviii, 932 p. ;, 28 cm. +
Publisher	Mosby Elsevier
Publishing place	St. Louis, Mo
Document type	Book
Accompanying material	1 CD-ROM (4 3/4 in.)
ISBN	9780323029643 ; 0323029647
Database	Catalogue of the US National Library of Medicine (NLM)

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Diagnosis of mast cell activation syndrome: a global "consensus-2".

Afrin, Lawrence B / Ackerley, Mary B / Bluestein, Linda S / Brewer, Joseph H / Brook, Jill B / Buchanan, Ariana D / Cuni, Jill R / Davey, William P / Dempsey, Tania T / Dorff, Shanda R / Dubravec, Martin S / Guggenheim, Alena G / Hindman, Kimberly J / Hoffman, Bruce / Kaufman, David L / Kratzer, Stephanie J / Lee, Theodore M / Marantz, Mindy S / Maxwell, Andrew J /

McCann, Kelly K / McKee, Dwight L / Menk Otto, Laurie / Pace, Laura A / Perkins, Dahra D / Radovsky, Laurie / Raleigh, Mary S / Rapaport, Sonia A / Reinhold, Emma J / Renneker, Mark L / Robinson, William A / Roland, Aaron M / Rosenbloom, E Scott / Rowe, Peter C / Ruhoy, Ilene S / Saperstein, David S / Schlosser, David A / Schofield, Jill R / Settle, Janet E / Weinstock, Leonard B / Wengenroth, Martina / Westaway, Mark / Xi, Shijun Cindy / Molderings, Gerhard J

Diagnosis (Berlin, Germany)

2020 Volume 8, Issue 2, Page(s) 137–152

Abstract: The concept that disease rooted principally in chronic aberrant constitutive and reactive activation of mast cells (MCs), without the gross MC neoplasia in mastocytosis, first emerged in the 1980s, but only in the last decade has recognition of "mast ... ...

Abstract	The concept that disease rooted principally in chronic aberrant constitutive and reactive activation of mast cells (MCs), without the gross MC neoplasia in mastocytosis, first emerged in the 1980s, but only in the last decade has recognition of "mast cell activation syndrome" (MCAS) grown significantly. Two principal proposals for diagnostic criteria have emerged. One, originally published in 2012, is labeled by its authors as a "consensus" (re-termed here as "consensus-1"). Another sizable contingent of investigators and practitioners favor a different approach (originally published in 2011, newly termed here as "consensus-2"), resembling "consensus-1" in some respects but differing in others, leading to substantial differences between these proposals in the numbers of patients qualifying for diagnosis (and thus treatment). Overdiagnosis by "consensus-2" criteria has potential to be problematic, but underdiagnosis by "consensus-1" criteria seems the far larger problem given (1) increasing appreciation that MCAS is prevalent (up to 17% of the general population), and (2) most MCAS patients, regardless of illness duration prior to diagnosis, can eventually identify treatment yielding sustained improvement. We analyze these proposals (and others) and suggest that, until careful research provides more definitive answers, diagnosis by either proposal is valid, reasonable, and helpful.
MeSH term(s)	Consensus ; Humans ; Mast Cells ; Mastocytosis/diagnosis
Language	English
Publishing date	2020-04-22
Publishing country	Germany
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Review
ISSN	2194-802X
ISSN (online)	2194-802X
DOI	10.1515/dx-2020-0005
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED